23andMe Funding Round

10/14/2015

Venture Equity

$115,000,000

Series E

This round of funding will enable us to further our vision for long term growth in our consumer and therapeutic businesses. This investment will enable the company to expand its operations and maximize the potential of its direct-to-consumer product in the US and abroad. The company expects to launch a new user experience that includes carrier status reports in the US, as well as enhanced tools and functionality for customers by the end of the year. The Series E financing will also provide capital for strategic infrastructure including new laboratory space for therapeutic research, a next generation sequencing laboratory as well as other investments in long-term growth.

Private & Independent

Enterprise IT

1390 Shorebird Way
Mountain View, CA 94043
USA

23andMe is the first and only genetic service available directly to you that includes reports that meet FDA standards.